The Agency for Toxic Substances and Disease Registry (ATSDR) is pleased to announce publication of research grant Notice of Funding Opportunity RFA-TS-21-001 Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis.
RFA-TS-21-001 may be viewed, and applications submitted, at: https://www.grants.gov/web/grants/view-opportunity.html?oppId=329684. Applications are due to CDC/ATSDR by March 29, 2021 at 5:00PM EST.
ATSDR is seeking investigator initiated research that will further the understanding of potential risk factors for ALS, while supporting the ATSDR National ALS Registry’s mission. The National ALS Registry’s goals are to estimate the number of new ALS cases each year, estimate the number of people who have ALS at a specific point in time, better understand who gets ALS, and identify what contributing factors, including environmental, may affect ALS. ATSDR is seeking investigator-initiated research that will identify and evaluate risk factors contributing to ALS, with preferred focus in this Notice of Funding Opportunity on factors related to military service, contact sports, traumatic brain injury, neuroinflammation and infectious agents.
ATSDR is especially interested in innovative research applications that propose to conduct an epidemiological investigation using the ATSDR National ALS Registry and/or using a third party ALS registry on risk factors related to military service, contact sports, traumatic brain injury, neuroinflammation and infectious agents. Examples of ALS registry research previously funded by ATSDR can be found at https://www.cdc.gov/als/
Eligibility for RFA-TS-21-001 is open to both United States and Foreign Organization applicant institutions, as specified in RFA-TS-21-001.
Second Level Review Considerations:
- Consideration for meritorious applications proposing to identify and evaluate risk factors for ALS in the context of past military service, contact sports, traumatic brain injury, neuroinflammation and infectious agents.
- Consideration for meritorious applications in which the contact Eligible PD/PI meets NIH Early Stage Investigator (ESI) status, as verified by the NIH Determination of Investigator Status process.
Applicants are encouraged to carefully review all RFA-TS-21-001 requirements and contact Dr. Marci Wright (email@example.com) with questions regarding eligibility and the scientific intent of this funding opportunity.